Table of Contents
A new study published today in the journal Cell reveals a surprising mechanism by which the gut generates long-term immunity to viruses, potentially paving the way for more effective vaccines against diseases like COVID-19, SARS-CoV-2, and avian flu. The research, led by scientists at the University of Toronto, identifies an atypical pathway used by immune cells in the gut to produce antibodies offering sustained protection.
Current vaccines, while effective at reducing severe illness from COVID-19 and the flu, ofen fall short in preventing initial infection. A truly effective vaccine, experts say, must stimulate a robust immune response at the body’s entry points – the nose, mouth, and airways. This “mucosal immunity” hinges on an antibody called IgA, abundant in the mucous membranes of the respiratory and digestive tracts and found in bodily fluids like saliva and tears.
“If you could make a mucosal immune response that’s durable,that’s the Holy Grail as then you’re blocking entry of the virus,” explained a senior immunology researcher and chair at the University of Toronto’s Temerty Faculty of Medicine. “If you block entry, then you’re not going to get infected and you’re not going to transmit the virus.”
the Challenge of Durable Mucosal Immunity
Creating vaccines that elicit a lasting IgA response has proven arduous. Previous research, including a 2020 study from the same team, demonstrated that while natural viral infections like SARS-CoV-2 trigger a local immune response, these responses tend to wane quickly.
“When we looked at the key IgA antibody that protects us against infection, those antibody levels really don’t last,” the researcher noted.However, scientists knew that long-lasting IgA responses were possible, citing the lifelong immunity conferred by oral vaccines against diseases like rotavirus and polio. This led them to hypothesize that the oral route and the small intestine might hold the key to sustained immunity.
A Novel Pathway in the Gut
To investigate this hypothesis, the research team, led by postdoctoral fellow Kei haniuda, focused on a mouse model of rotavirus infection. Their findings revealed a surprising shortcut in the gut’s IgA production process. The gut IgA response relies on dialog between T cells and B cells,but it bypasses a typical step where viral components are initially presented to T cells. This streamlined process results in a faster and more potent IgA antibody response.
Remarkably, the IgA antibodies produced were not only protective but also persisted for at least 200 days post-infection. “The IgA response was shockingly long lived,” the researcher stated. “Despite the virus being cleared within about 10 days,the response continued to improve over time,so you end up having IgA antibodies that are very,very good at recognizing rotavirus.”
Implications for Future Vaccine Progress
The researchers believe the unique environment of the gut – its anatomy and complex microbial community – may be responsible for this exceptional durability. these findings bolster the potential of oral vaccination as a strategy against respiratory viruses.However, developing such vaccines presents important challenges.
The team is now focusing on developing an oral vaccine against highly pathogenic avian influenza, or bird flu. They are also exploring ways to enhance the “mucosal-friendliness” of existing flu and COVID-19 vaccines, currently administered by injection, by leveraging the microbiome to boost IgA responses.
“We learned how the immune cells get activated,how we can detect them and what signals are critical for their development,” the researcher concluded. “We can now apply that knowledge to developing better vaccines.”
more information: Kei haniuda et al, Mucosal viral infection elicits long-lived IgA responses via type 1 follicular helper T cells, Cell (2025). DOI: 10.1016/j.cell.2025.07.022.
Journal information: Cell.
